Literature DB >> 10203284

Oral contraceptive use and risk of gestational trophoblastic tumors.

J R Palmer1, S G Driscoll, L Rosenberg, R S Berkowitz, J R Lurain, J Soper, L B Twiggs, D M Gershenson, E I Kohorn, M Berman, S Shapiro, R S Rao.   

Abstract

BACKGROUND: Gestational trophoblastic disease refers to a spectrum of rare benign and malignant gynecologic disorders whose pathogenesis is not well understood. Recent studies from China and the United States have raised the hypothesis that long-term use of oral contraceptives before conception may increase the risk of gestational trophoblastic tumors. A multicenter case-control study of gestational trophoblastic tumors was undertaken to test this hypothesis.
METHODS: Telephone interviews were conducted with 235 case patients, including 50 with gestational choriocarcinoma, and 413 control subjects matched on recentness of pregnancy, age at pregnancy, and area of residence. Relative risks (odds ratios) were computed by conditional logistic regression. Reported P values are two-sided.
RESULTS: The relative risk estimate for ever having used oral contraceptives before the index pregnancy was 1.9 (95% confidence interval [CI] = 1.2-3.0), and the risk increased with duration of use (P for trend = .05). The estimate was highest for women who used oral contraceptives during the cycle in which they became pregnant (relative risk = 4.0; 95% CI=1.6-10), but there was no consistent pattern according to the time interval since last use. Separate analyses of choriocarcinoma and persistent mole yielded similar results, i.e., the relative risk estimates for oral contraceptive use were 2.2 (95% CI=0.8-6.4) and 1.8 (95% CI=1.0-3.0), respectively. Control for the number of sexual partners, which was independently associated with risk (P for trend = .05), did not materially change the results.
CONCLUSIONS: This study, the largest to date, indicates that long duration of oral contraceptive use before conception increases the risk of gestational trophoblastic tumors. These findings may provide clues to the pathogenesis of this rare disease. Changes in use of oral contraceptives are not warranted, however, because the incidence attributable to oral contraceptive use is very low.

Entities:  

Keywords:  Americas; Case Control Studies; Contraception; Contraceptive Methods--side effects; Developed Countries; Diseases; Evaluation; Family Planning; Hydatidiform Mole; North America; Northern America; Oral Contraceptives--side effects; Pregnancy Complications; Research Methodology; Research Report; Risk Assessment--women; Studies; United States; Women

Mesh:

Substances:

Year:  1999        PMID: 10203284     DOI: 10.1093/jnci/91.7.635

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  2 in total

1.  Hydatidiform moles among patients with incomplete abortion in Mwanza City, North western Tanzania.

Authors:  Bernard Kitange; Dismas Matovelo; Eveline Konje; Anthony Massinde; Peter Rambau
Journal:  Afr Health Sci       Date:  2015-12       Impact factor: 0.927

2.  Recurrent hydatidiform mole: A case report of six consecutive molar pregnancies complicated by choriocarcinoma, and review of the literature.

Authors:  Ahlam A Al-Ghamdi
Journal:  J Family Community Med       Date:  2011-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.